Cochrane, T. (Tara)

Author search.filters.isAuthorOfPublication.0eaff57f-4239-41e3-8228-9be308f0e487

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
    (2020) Moreau, P. (Philippe); Cochrane, T. (Tara); Ukropec, J. (Jon); Kaufman, J.L. (Jonathan L.); Usmani, S.Z. (Saad Z.); Kim, K. (Kihyun); Morton, J. (James); Sutherland, H.J. (Heather J.); Magen, H. (Hila); Krevvata, M. (Maria); Iida, S. (Shinsuke); Kim, J.S. (Jin Sheok); Benboubker, L. (Lotfi); Takezako, N. (Naoki); Casneuf, T. (Tineke); White, D.J. (Darrell J.); Dimopoulos, M.A. (Meletios A.); Trivedi, S. (Sonali); Prince, H.M. (H. Miles); Avet-Loiseau, H. (Herve); Oriol, A. (Albert); Leiba, M. (Merav); San-Miguel, J.F. (Jesús F.); Cook, G. (Gordon); Kobos, R. (Rachel); O’Rourke, L. (Lisa)
    High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10–5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.